Page 154 - Binder2

Biologics will continue to rise. The question is whether
they’ll endure.

That’s what this book is about.
That’s what the rebellion is for.
And that’s what we build next.

3.9 – Redesigning the Pipeline: What
a Tolerance-First Biotech Looks Like

If immune compatibility is the future, then it's time to ask
the next question:
What does a biotech company built around that future
actually look like?

Because most companies today aren’t structured to prevent
tolerization.
They’re structured to identify targets, develop binders, run
fast trials, and get to market.
The immune system is considered—but late. Usually in
response to a problem, not as part of the plan.

A tolerance-first biotech turns that model upside down.

It doesn’t treat the immune system as a constraint.
It treats it as the primary design environment.
And everything else—target, delivery, trial structure, IP—
flows from that foundation.

Rethinking the tried-and-true pipeline isn’t easy. It's
something that pushes against the grain.

152